RxDoctor Payments Data

Jonathan Jacobs

Internal Medicine · Overland Park, KSNPI 1164458907

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,421 and has fallen 67.4% since, to $463 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,688in general payments, 2019–2025

Across 338 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$938
  • AbbVie$894
  • Novo Nordisk$611
  • Amgen$388
  • Boehringer Ingelheim$318
  • AstraZeneca$288
  • plus $2K from 34 others
$821,651in research payments, 2019–2025

Across 48 payments — averaging $17,118 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$822K

What the payments were for

  • Food & beverage$5,62399%
  • Education$351%
  • Other$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,688 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$84,569
OzempicSemaglutide36$38,576
MounjaroTirzepatide27$30,868
XareltoRivaroxaban21$20,366
RytaryCarbidopa/Levodopa14$19,813
JardianceEmpagliflozin26$19,760
LinzessLinaclotide22$16,047
MyrbetriqMirabegron13$13,952
Tresiba Flextouch U-200Insulin Degludec15$13,493
GemtesaVibegron16$13,336
OxycontinOxycodone Hcl24$9,183
Emgality SyringeGalcanezumab-Gnlm12$7,975
PaxlovidNirmatrelvir/Ritonavir22$2,859
Gabapentin90$2,239
Memantine Hcl58$2,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$210$87,428118 claims
Novo NordiskOzempic$611$38,57636 claims
Lilly USA, LLCMounjaro$938$30,86827 claims
Amneal Pharmaceuticals LLCRytary, Levothyroxine Sodium$69$20,700115 claims
Johnson & JohnsonXarelto$103$20,36621 claims
Boehringer IngelheimJardiance$318$19,76026 claims
AbbVieLinzess, Synthroid$894$16,65533 claims
Sumitomo Pharma America, Inc.Gemtesa$26$13,33616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →